Assetmark Inc. Has $62.58 Million Position in Pfizer Inc. $PFE

Key Points

• Assetmark Inc. increased its Pfizer stake by 3.5% in Q4 to 2,513,315 shares—worth about $62.58 million after adding 84,848 shares.
• Multiple large institutional investors also boosted positions (e.g., Franklin +47.8%, Neuberger Berman +203.8%, Ameriprise +48.2%, AQR +120.9%), with 68.36% of Pfizer held by institutions.
• Analyst views are mixed: MarketBeat shows a consensus "Hold" with an average price target of $28.24; Pfizer beat Q4 EPS estimates but revenue declined 1.2% year‑over‑year and Q1 profits are expected to fall.

Assetmark Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,513,315 shares of the biopharmaceutical company's stock after buying an additional 84,848 shares during the quarter. Assetmark Inc.'s holdings in Pfizer were worth $62,582,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its position in shares of Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock worth $638,787,000 after buying an additional 8,108,887 shares during the period. Neuberger Berman Group LLC grew its position in Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock valued at $229,346,000 after acquiring an additional 6,045,763 shares during the period. Ameriprise Financial Inc. raised its stake in Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock worth $468,174,000 after acquiring an additional 5,978,927 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Pfizer by 120.9% during the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company's stock valued at $230,986,000 after acquiring an additional 5,202,884 shares during the period. Finally, Amundi boosted its stake in shares of Pfizer by 10.8% in the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company's stock valued at $1,096,380,000 after purchasing an additional 4,043,413 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PFE. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. Zacks Research upgraded Pfizer from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 24th. Guggenheim raised their price target on Pfizer from $35.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, March 24th. Finally, Morgan Stanley lifted their price objective on Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of "Hold" and an average price target of $28.24.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: UBS raised its price target on Pfizer from $25 to $27 (maintaining a neutral rating), a modest vote of confidence that can provide short‑term support. UBS price target note
• Positive Sentiment: One outlet raised Pfizer’s target to $28, which could reinforce upside among income‑seeking investors. Price Target Raised to $28
• Positive Sentiment: Pfizer renewed a licensing deal to keep Trellus Health’s patient‑education content in its IBD digital app — a small but constructive commercial/partnership development. Trellus Health deal renewal
• Positive Sentiment: Dividend‑focused pieces continue to list Pfizer among blue‑chip payers, supporting longer‑term income demand for the stock. Dividend income article
• Neutral Sentiment: Wells Fargo issued a Hold on PFE, leaving its recommendation unchanged and signaling no near‑term conviction to add or cut exposure. Wells Fargo Hold rating
• Neutral Sentiment: Pfizer Limited corrected a technical XBRL filing error — a housekeeping item that reduces disclosure risk but is unlikely to move the stock materially. XBRL filing correction
• Neutral Sentiment: Recent news pieces noted Pfizer has recently outperformed the broader market on a short‑term basis, but that momentum has not removed near‑term fundamental concerns. Outperforms broader market article
• Negative Sentiment: An earnings preview warns analysts expect Q1 profits to decline in the low double‑digit percentage range, a substantive headwind that likely explains downgrades/discounting by some investors ahead of the report. Earnings preview
• Negative Sentiment: Bank of America trimmed its price target to $26 (from $27) while keeping a Neutral rating — another sign analysts are tempering expectations into the quarter. BofA lowers PT to $26

Pfizer Price Performance

PFE opened at $27.13 on Wednesday. The company has a fifty day moving average price of $27.24 and a two-hundred day moving average price of $26.01. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $21.87 and a 52 week high of $28.75. The firm has a market capitalization of $154.27 billion, a PE ratio of 19.95 and a beta of 0.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analysts' expectations of $16.93 billion. During the same period in the prior year, the business posted $0.63 EPS. Pfizer's revenue was down 1.2% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.